

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Stanka PERC et al.

Serial No.: 10/531,540

Filed: April 15, 2005

For: Pharmaceutical Formulation of Olanzapine

Examiner: Jean -Louis, Samira JM  
Group Art: 1617

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

S I R:

In compliance with the duty of disclosure under 37 C.F.R. §1.56 and in accordance with the practice under 37 C.F.R. §§1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.

This information is being submitted after issuance of a Final Office Action on the merits, or after issuance of a Notice of Allowance, but before payment of the Issue Fee.

**STATEMENT**

Each item of information contained in the Information Disclosure Statement was first cited in a communication received from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b),

or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

Please charge our Patent and Trademark Office Deposit Account No. 03-2412 in the amount of \$180.00 in payment of the appropriate fee. It is believed that no additional fees or charges are required at this time in connection with the present application. However, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

Respectfully submitted,  
COHEN PONTANI LIEBERMAN & PAVANE LLP

By /Kent H. Cheng/  
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: March 30, 2010